Koers Herantis Pharma Oyj Nasdaq Helsinki
Aandelen
FI4000087861
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 1,3 mln. 1,39 mln. | Omzet 2025 * | - | Marktkapitalisatie | 29,43 mln. 31,47 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -3 mln. -3,21 mln. | Nettowinst (verlies) 2025 * | -4 mln. -4,28 mln. | EV/omzet 2024 * | 19,4 x |
Nettoliquiditeiten 2024 * | 4,2 mln. 4,49 mln. | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 69,93% |
Recentste transcriptie over Herantis Pharma Oyj
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | - | 01-01-08 | |
Antti Vuolanto
CEO | Chief Executive Officer | - | 12-02-18 |
Tone Kvåle
DFI | Director of Finance/CFO | 55 | 26-10-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 53 | 01-01-14 | |
Director/Board Member | 53 | 11-03-20 | |
Chairman | 64 | 01-01-12 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,73 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |